CoChat
Sign Up
Cited by 317

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies

Maron, Barry J., Rowin, Ethan J., Casey, Susan A., Link, Mark S., Lesser, John R., Chan, Raymond H.M., Garberich, Ross F., Udelson, James E., Maron, Martin S.·2015·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2015.02.061
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2015.02.061

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The decrease in hypertrophic cardiomyopathy related mortality, from 3-6% a year in early cohorts to the current 0.5% year, has been attributed in part to the increasing identification of patients with hypertrophic cardiomyopathy at risk for sudden death with subsequent ICD implantation.

    “the decrease in hypertrophic cardiomyopathy related mortality, from 3-6% a year in early cohorts to the current 0.5% year, 95 has been attributed in part to the increasing identification of patients with hypertrophic cardiomyopathy at risk for sudden death with subsequent ICD implantation.”

    From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [95]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Maron, 2013, Hypertrophic cardiomyopathy, Lancet, 381, 242, 10.1016/S0140-6736(12)60397-3 · DOI · Paper page
  2. Maron, 2010, Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy, Circulation, 121, 445, 10.1161/CIRCULATIONAHA.109.878579 · DOI
  3. O’Mahony, 2013, Heart, 99, 534, 10.1136/heartjnl-2012-303271 · DOI
  4. Maron, 2003, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 · DOI
  5. Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  6. Elliott, 2000, Sudden death in hypertrophic cardiomyopathy: identification of high risk patients, J Am Coll Cardiol, 36, 2212, 10.1016/S0735-1097(00)01003-2 · DOI
  7. Maron, 2000, Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population, Circulation, 102, 858, 10.1161/01.CIR.102.8.858 · DOI · Paper page
  8. Maron, 2012, Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease, Circulation, 126, 1640, 10.1161/CIRCULATIONAHA.112.123174 · DOI
  9. Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, 298, 405, 10.1001/jama.298.4.405 · DOI
  10. Schinkel, 2012, Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis, Circ Heart Fail, 5, 552, 10.1161/CIRCHEARTFAILURE.112.969626 · DOI
  11. Vriesendorp, 2013, Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications, Am Heart J, 166, 496, 10.1016/j.ahj.2013.06.009 · DOI
  12. Maron, 2000, Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N Engl J Med, 342, 365, 10.1056/NEJM200002103420601 · DOI · Paper page
  13. Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 11, 216, 10.1161/CIRCULATIONAHA.105.583500 · DOI
  14. Maron, 2010, Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy, Circ Heart Fail, 3, 574, 10.1161/CIRCHEARTFAILURE.109.922872 · DOI
  15. Kato, 2012, Cardiac transplantation in patients with hypertrophic cardiomyopathy, Am J Cardiol, 110, 568, 10.1016/j.amjcard.2012.04.030 · DOI
  16. Maron, 2013, Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥ 60 years of age, Circulation, 127, 585, 10.1161/CIRCULATIONAHA.112.136085 · DOI · Paper page
  17. Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006 · DOI
  18. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  19. Desai, 2014, Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes, J Am Coll Cardiol Img, 7, 26, 10.1016/j.jcmg.2013.08.010 · DOI
  20. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  21. Maron, 2008, Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy, Circulation, 118, 1541, 10.1161/CIRCULATIONAHA.108.781401 · DOI
  22. Spirito, 2014, Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors, Am J Cardiol, 113, 1550, 10.1016/j.amjcard.2014.01.435 · DOI
  23. Maron, 2008, Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status, Am J Cardiol, 101, 544, 10.1016/j.amjcard.2007.09.101 · DOI
  24. Maron, 2011, Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 57, 2454, 10.1016/j.jacc.2011.03.021 · DOI
  25. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  26. Sorajja, 2012, Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Circulation, 126, 2374, 10.1161/CIRCULATIONAHA.111.076257 · DOI
  27. Maron, 2013, Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 1527, 10.1016/j.jacc.2013.01.037 · DOI
  28. McKenna, 1984, Hypertrophic cardiomyopathy: an important cause of sudden death, Arch Dis Child, 59, 971, 10.1136/adc.59.10.971 · DOI
  29. Maron, 1976, Asymmetric septal hypertrophy in childhood, Circulation, 53, 9, 10.1161/01.CIR.53.1.9 · DOI
  30. Shah, 1974, The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy, Circ Res, 35, 179
  31. Hardarson, 1973, Prognosis and mortality of hypertrophic obstructive cardiomyopathy, Lancet, 2, 1462, 10.1016/S0140-6736(73)92730-X · DOI
  32. Spirito, 1989, Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population, N Engl J Med, 320, 749, 10.1056/NEJM198903233201201 · DOI
  33. Maron, 1999, Clinical course of hypertrophic cardiomyopathy in a regional United States cohort, JAMA, 281, 650, 10.1001/jama.281.7.650 · DOI
  34. Wheeler, 2015, Hypertrophic cardiomyopathy: can the horse be put back in the barn?, J Am Coll Cardiol, 65, 570, 10.1016/j.jacc.2014.12.004 · DOI
  35. Moss, 1996, Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia, N Engl J Med, 335, 1933, 10.1056/NEJM199612263352601 · DOI · Paper page
  36. Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  37. Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088 · DOI
  38. Maron, 2008, Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy, J Cardiovasc Electrophysiol, 19, 1118, 10.1111/j.1540-8167.2008.01147.x · DOI
  39. McLeod, 2007, Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy, Eur Heart J, 28, 2583, 10.1093/eurheartj/ehm117 · DOI
  40. Maron, 2007, Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy, Circulation, 116, 196, 10.1161/CIRCULATIONAHA.107.691378 · DOI
  41. Maron, 2013, Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative, Am J Cardiol, 112, 1512, 10.1016/j.amjcard.2013.06.040 · DOI
  42. Maron, 2009, Hypertrophic cardiomyopathy centers, Am J Cardiol, 104, 1158, 10.1016/j.amjcard.2009.05.064 · DOI

Cited by

Sorted by citations

Metadata

Authors
Maron, B. J., Rowin, E. J., Casey, S. A., Link, M. S., Lesser, J. R., Chan, R. H. M., Garberich, R. F., Udelson, J. E., & Maron, M. S.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2015-05
Volume
65
Issue
18
Pages
1915-1928
ISSN
0735-1097
DOI
10.1016/j.jacc.2015.02.061
Cited by
317
References
5
Language
en
Licence
Funders
Medtronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review